Heart, lung & circulation
Mavacamten in Obstructive Hypertrophic Cardiomyopathy-A First Australian Experience.
Antony Chun Fai So, Kathryn A Davison, Teresa Hecker, Rahil Moriswala, Sivabaskari Pasupathy, Ranjit J Shah, Joseph B Selvanayagam
Published: 202610.1016/j.hlc.2025.08.019
Abstract
BACKGROUND & AIMS: Mavacamten, a first-in-class, cardiac-specific myosin inhibitor, has recently been approved in Australia as second-line therapy in patients with obstructive hypertrophic cardiomyopathy (oHCM) and New York Heart Association (NYHA) c…
Preview only. Read the full abstract at the source